Other
Change in AR
Alnylam Pharmaceuticals Change in AR decreased by 72.4% to $110.42M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1385.4%, from $7.43M to $110.42M. Over 3 years (FY 2021 to FY 2024), Change in AR shows a downward trend with a -5.3% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementIncome Statement
SectionOther
CategoryLiquidity
SignalLower is better
VolatilityModerate
First reportedQ1 2016
Last reportedQ1 2026Apr 30, 2026
How to read this metric
A significant increase may signal aggressive revenue recognition or collection issues, while a decrease suggests improved cash conversion cycles.
Detailed definition
The net change in the balance of accounts receivable during the reporting period, representing the difference between cr...
Peer comparison
Should track closely with revenue growth; significant deviations from revenue trends warrant investigation.
Metric ID:
anet_change_in_accounts_receivableHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $35.31M | -$3.67M | $59.45M | -$39.70M | -$6.40M | $38.42M | $53.27M | -$19.15M | $2.97M | $107.99M | $0.00 | -$410.00K | -$9.64M | $37.09M | $59.51M | $7.43M | $136.91M | $399.86M | $110.42M |
| QoQ Change | — | -110.4% | >999% | -166.8% | +83.9% | +700.5% | +38.6% | -136.0% | +115.5% | >999% | -100.0% | — | <-999% | +484.8% | +60.4% | -87.5% | >999% | +192.1% | -72.4% |
| YoY Change | — | — | — | — | -118.1% | >999% | -10.4% | +51.8% | +146.4% | +181.1% | -100.0% | +97.9% | -424.6% | -65.7% | — | >999% | >999% | +978.0% | >999% |
Range-$39.70M – $399.86M
CAGR+28.8%
Avg YoY Growth+478.7%
Median YoY Growth+122.1%
Change in AR at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's change in ar?
- Alnylam Pharmaceuticals (ALNY) reported change in ar of $110.42M in Q1 2026.
- How has Alnylam Pharmaceuticals's change in ar changed year-over-year?
- Alnylam Pharmaceuticals's change in ar increased by 1385.4% year-over-year, from $7.43M to $110.42M.
- What is the long-term trend for Alnylam Pharmaceuticals's change in ar?
- Over 3 years (2021 to 2024), Alnylam Pharmaceuticals's change in ar has grown at a -5.3% compound annual growth rate (CAGR), from $101.80M to $86.55M.
- What does change in ar mean?
- The net increase or decrease in money owed to the company by customers.